[0178] Kessler, Sonnega, Bromet, Hughes, & Nelson, 1995, Posttraumatic stress disorder in the National Comorbidity Survey. *Arch. Gen. Psychiatry,* 52:1048-1060.

[0179] Kirschner D A, Gross A A, Hidalgo M M, Inouye H, Gleason K A, Abdelsayed G A, Castillo G M, Snow A D, Pozo-Ramajo A, Petty S A, Decatur S M (2008) Fiber diffraction as a screen for amyloid inhibitors. *Curr Alzheimer Res* 5, 288-307.

[0180] Kudo, Y., Okamura, N., Furumoto, S., Tashiro, M., Furukawa, K. et al. (2007) "2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients" *J. Nucl. Med.,* 48:553-561.

[0181] Levin E D (2002) Nicotinic receptor subtypes and cognitive function. *J Neurobiol* 53, 633-640.

[0182] Lindahl E, Hess, B., and van der Spoel, D. (2001) GROMACS 3.0: a package for molecular simulation and trajectory analysis. 7, 306-317.

[0183] Merchant C, Tang M X, Albert S, Manly J, Stern Y, Mayeux R (1999) The influence of smoking on the risk of Alzheimer's disease. *Neurology* 52, 1408-1412.

[0184] Miyamoto S, and Kollman, P. A (1992) SETTLE: An analytical version of the SHAKE and RATTLE algorithms for rigid water models. *Journal of Computational Chemistry* 13, 952-962.

[0185] Moore S A, Huckerby T N, Gibson G L, Fullwood N J, Turnbull S, Tabner B J, El-Agnaf O M, Allsop D (2004) Both the D-(+) and L-(−) enantiomers of nicotine inhibit Abeta aggregation and cytotoxicity. *Biochemistry* 43, 819-826.

[0186] Morris G M, Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K. and Olson, A. J. (1998) Automated Docking Using a Lamarckian Genetic Algorithm and and Empirical Binding Free Energy Function. *Journal of Computational Chemistry* 19, 1639-1662.

[0187] Necula M, Kayed R, Milton S, Glabe C G (2007) Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. *J Biol Chem* 282, 10311-10324.

[0188] Nordberg A, Hellstrom-Lindahl E, Lee M, Johnson M, Mousavi M, Hall R, Perry E, Bednar I, Court J (2002) Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). *J Neurochem* 81, 655-658.

[0189] Oddo S, Caccamo A, Green K N, Liang K, Tran L, Chen Y, Leslie F M, LaFerla F M (2005) Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. *Proc Natl Acad Sci USA* 102, 3046-3051.

[0190] Ono K, Hasegawa K, Yamada M, Naiki H (2002) Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro. *Biol Psychiatry* 52, 880-886.

[0191] Solomon S D & Davidson, (1997). Trauma: prevalence, impairment, service use, and cost. *J Clin Psychiatry.* 58 Suppl 9. 5-11.

[0192] Salomon A R, Marcinowski K J, Friedland R P, Zagorski M G (1996) Nicotine inhibits amyloid formation by the beta-peptide. *Biochemistry* 35, 13568-13578.

[0193] Schnurr & Jankowski, (1999). Physical health and post-traumatic stress disorder: review and synthesis. *Semin Clin Neuropsychiatry* 4(4):295-304.

[0194] Schuettelkopf A. W. and Van Aalten DMF (2004) PRODRG—a tool for high-throughput crystallography of protein-ligand complexes. *Acta Crystallographica* 60, 1355-1363.

[0195] Szymanska I, Radecka H, Radecki J, Kaliszan R (2007) Electrochemical impedance spectroscopy for study of amyloid beta-peptide interactions with (−) nicotine ditartrate and (−) cotinine. *Biosens Bioelectron* 22, 1955-1960.

[0196] Terry A V, Jr., Hernandez C M, Hohnadel E J, Bouchard K P, Buccafusco J J (2005) Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition. *CNS Drug Rev* 11, 229-252.

[0197] Tong L, Balazs R, Thornton P L, Cotman C W (2004) Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. *J Neurosci* 24, 6799-6809.

[0198] Triguero L, Singh R, Prabhakar R (2008) Comparative molecular dynamics studies of wild-type and oxidized forms of full-length Alzheimer amyloid beta-peptides Abeta(1-40) and Abeta(1-42). *J Phys Chem B* 112, 7123-7131.

[0199] Unger C, Hedberg M M, Mustafiz T, Svedberg M M, Nordberg A (2005) Early changes in Abeta levels in the brain of APPswe transgenic mice—implication on synaptic density, alpha7 neuronal nicotinic acetylcholine- and N-methyl-D-aspartate receptor levels. *Mol Cell Neurosci* 30, 218-227.

[0200] Yolton K, Dietrich K, Auinger P, Lanphear B P, Hornung R (2005) Exposure to environmental tobacco smoke and cognitive abilities among U.S. children and adolescents. *Environ Health Perspect* 113, 98-103.

[0201] York D M, Wlodawer A, Pedersen L G, Darden T A (1994) Atomic-level accuracy in simulations of large protein crystals. *Proc Natl Acad Sci USA* 91, 8715-8718.

I claim:

1. A method for treating and/or preventing a disease or condition associated with the accumulation and/or aggregation of Abeta peptide in neural tissue, or for treating and/or preventing a disorder or condition associated with Down's syndrome, or for treating and/or preventing a stress disorder or condition, said method comprising administering an effective amount of cotinine, or a composition comprising cotinine, or an isomer or racemate thereof, or a pharmaceutically acceptable salt thereof, to a person or animal.

2. The method according to claim **1**, wherein said method further comprises administering one or more drugs for the treatment or prevention of a neurodegenerative condition.

3. The method according to claim **2**, wherein said one or more drug is donepezil (ARICEPT), galantamine (RAZADYNE), rivastigmine (EXELON), memantine (AKATINOL), rasagiline (AZILECT), selegiline (ELDEPRYL), L-dopa (LEVODOPA, SINEMET, PARCOPA, STALEVO, MADOPAR), carbidopa (LODOSYN), or benserazide, or an isomer or analog thereof, or a pharmaceutically acceptable salt thereof.

4. The method according to claim **1**, wherein said method further comprises administering one or more drugs for the treatment of a stress disorder or condition.

5. The method according to claim **4**, wherein said one or more drug is a selective serotonin reuptake inhibitor (SSRI); a serotonin-norepinephrine reuptake inhibitor (SNRI); a tri-